Lingyun Wu Selected Research

Cystathionine gamma-Lyase (Cysteine Desulfhydrase)

1/2021	The interaction of disulfiram and H2S metabolism in inhibition of aldehyde dehydrogenase activity and liver cancer cell growth.
7/2020	Cystathionine gamma-lyase/H2S system suppresses hepatic acetyl-CoA accumulation and nonalcoholic fatty liver disease in mice.
2/2018	Cystathionine gamma-lyase/hydrogen sulfide system is essential for adipogenesis and fat mass accumulation in mice.
11/2017	Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency.
11/2015	H2S-induced S-sulfhydration of pyruvate carboxylase contributes to gluconeogenesis in liver cells.
10/2008	H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lingyun Wu Research Topics

Disease

23	Hypertension (High Blood Pressure) 01/2017 - 03/2002
20	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 03/2007
18	Neoplasms (Cancer) 10/2022 - 05/2004
17	Insulin Resistance 01/2021 - 03/2003
11	Inflammation (Inflammations) 10/2022 - 02/2012
10	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2021 - 11/2013
7	Brain Injuries (Brain Injury) 01/2021 - 01/2014
6	Stroke (Strokes) 05/2022 - 05/2004
6	Neoplasm Metastasis (Metastasis) 03/2021 - 09/2012
6	Atherosclerosis 01/2021 - 05/2004
6	Hypoxia (Hypoxemia) 01/2016 - 02/2012
6	Type 2 Diabetes Mellitus (MODY) 01/2013 - 10/2004
5	Obesity 01/2021 - 09/2004
5	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 12/2011
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2017 - 01/2011
5	Ischemia 10/2016 - 07/2010
5	Infections 05/2015 - 03/2006
4	Hyperglycemia 08/2011 - 03/2003
3	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 11/2018
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2011
3	Breast Neoplasms (Breast Cancer) 10/2020 - 03/2016
3	Brain Edema (Cerebral Edema) 01/2019 - 01/2014
3	Traumatic Brain Injuries (Traumatic Brain Injury) 11/2016 - 01/2014
3	Body Weight (Weight, Body) 10/2011 - 09/2004
2	Liver Neoplasms (Liver Cancer) 01/2021 - 11/2018
2	Carcinogenesis 12/2020 - 08/2016
2	Atrophy 10/2020 - 01/2020
2	Fibrosis (Cirrhosis) 07/2020 - 10/2018
2	Cognitive Dysfunction 01/2014 - 11/2013
2	Necrosis 11/2013 - 05/2013
2	Neointima 03/2012 - 04/2007
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2011 - 09/2009
2	Vascular Remodeling 10/2011 - 10/2006
2	Glucose Intolerance 03/2011 - 01/2010

Drug/Important Bio-Agent (IBA)

20	Pyruvaldehyde (Methylglyoxal)IBA 01/2017 - 03/2002
19	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 03/2003
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2004
15	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 01/2021 - 04/2007
10	EnzymesIBA 01/2021 - 06/2007
10	Insulin (Novolin)FDA Link 04/2013 - 03/2003
8	sodium bisulfide (NaHS)IBA 10/2022 - 04/2007
8	Decitabine FDA Link 03/2016 - 05/2012
7	CytokinesIBA 10/2020 - 11/2007
6	Cystathionine gamma-Lyase (Cysteine Desulfhydrase)IBA 01/2021 - 10/2008
6	GasotransmittersIBA 01/2021 - 01/2011
5	Biomarkers (Surrogate Marker)IBA 10/2022 - 08/2016
5	Messenger RNA (mRNA)IBA 11/2021 - 07/2006
5	Adenosine Triphosphate (ATP)IBA 01/2021 - 12/2007
5	AntioxidantsIBA 01/2020 - 10/2004
4	Pharmaceutical PreparationsIBA 01/2020 - 11/2005
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 10/2004
4	LyasesIBA 03/2017 - 01/2011
4	CystathionineIBA 03/2017 - 01/2011
4	FructoseIBA 01/2017 - 12/2007
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2016 - 09/2009
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2016 - 09/2009
4	HomoharringtonineIBA 01/2016 - 09/2009
4	Superoxides (Superoxide)IBA 10/2011 - 03/2003
4	Thioctic Acid (Lipoic Acid)IBA 10/2011 - 03/2003
4	Advanced Glycation End ProductsIBA 09/2008 - 03/2003
3	InterferonsIBA 01/2021 - 05/2013
3	Estrogens (Estrogen)FDA Link 01/2021 - 01/2012
3	LigandsIBA 01/2020 - 03/2016
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 03/2016
3	Neuroprotective AgentsIBA 01/2018 - 10/2015
3	Biological ProductsIBA 04/2016 - 05/2010
3	sulforaphaneIBA 01/2016 - 02/2006
3	Vasodilator Agents (Vasodilators)IBA 01/2011 - 07/2003
2	Angiotensin IIIBA 10/2022 - 01/2020
2	RNA (Ribonucleic Acid)IBA 10/2022 - 01/2019
2	Glucagon-Like Peptide-1 ReceptorIBA 01/2021 - 01/2018
2	SulfurIBA 01/2021 - 12/2011
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 10/2020
2	Exenatide (Byetta)FDA Link 01/2021 - 01/2018
2	Nonesterified Fatty Acids (NEFA)IBA 07/2020 - 10/2011
2	LipidsIBA 07/2020 - 01/2020
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 03/2016
2	Interleukin-17 (Interleukin 17)IBA 01/2020 - 05/2013
2	Chemokine ReceptorsIBA 01/2020 - 01/2020
2	Interleukin-17 ReceptorsIBA 01/2020 - 05/2013
2	AndrogensIBA 01/2016 - 07/2014
2	Androgen Antagonists (Antiandrogens)IBA 01/2016 - 07/2014
2	SaltsIBA 01/2016 - 10/2004
2	Androgen Receptors (Androgen Receptor)IBA 01/2016 - 07/2014
2	Lipoproteins (Lipoprotein)IBA 11/2015 - 09/2014
2	Anti-Bacterial Agents (Antibiotics)IBA 08/2014 - 07/2011
2	gentamicin CIBA 08/2014 - 07/2011
2	AminoglycosidesIBA 08/2014 - 07/2011
2	CholesterolIBA 02/2014 - 06/2013
2	Fructose-Bisphosphate Aldolase (Aldolase)IBA 04/2013 - 12/2011
2	CarbohydratesIBA 01/2013 - 03/2011
2	Alkaline PhosphataseIBA 09/2012 - 03/2007
2	glucoraphaninIBA 02/2012 - 02/2006
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2011 - 09/2004
2	propargylglycineIBA 08/2011 - 01/2009

Therapy/Procedure

14	Therapeutics 12/2020 - 10/2004
5	Drug Therapy (Chemotherapy) 10/2020 - 09/2012
3	Radiotherapy 01/2021 - 06/2018
3	Ischemic Postconditioning 01/2016 - 04/2014
2	Castration 01/2016 - 07/2014